We are excited to collaborate with partners to bring our unique computationally designed antibodies to more indication, more targets and hence to more patients. Our partnerships bring more smart antibodies into the clinic by leveraging the development capabilities of our carefully selected partners.

Our Partners

Nektar Therapeutics

In 2021, we entered into a research partnership with Nektar Therapeutics to collaborate on the development of an agonist anti-TNFR2 antibody for the treatment of autoimmune diseases.

Learn More

Eli Lilly

We are proud of our research collaboration with Eli Lilly to discover and develop a potential new antibody-based therapy for the treatment of diabetes. This innovative approach to diabetes treatment makes use of our multibody technology — an antibody engineered to bind to two or more targets on each of its two arms.

Learn More

Aulos Bioscience

We collaborated with ATP, a leading life sciences venture capital firm, to launch Aulos Bioscience. This new company Is developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors. Working with Aulos Bioscience, we advanced a new antibody AU-007, into a Phase 1/2 human trial in Australia.

Learn More

Interested in Collaborating?

We’re always excited to explore opportunities for new partnerships. If you have a need, we’d love to hear from you.

Get in Touch